Inspiration Biopharmaceuticals anuncia la suspensión de ensayos clínicos que evalúan IB1001 para el tratamiento y la prevención del sangrado en la hemofilia B

Inspiration releases an important update about their clinical trial program for IB1001, an intravenous recombinant factor IX (rFIX) product that is being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. Click here for the official IBI press release.

es_PREspañol de Puerto Rico